BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 10667640)

  • 1. Clinical efficacy of micronized purified flavonoid fraction (MPFF) in edema.
    Olszewski W
    Angiology; 2000 Jan; 51(1):25-9. PubMed ID: 10667640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacologic aspects of a phlebotropic drug in CVI-associated edema.
    Ramelet AA
    Angiology; 2000 Jan; 51(1):19-23. PubMed ID: 10667639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic venous insufficiency: worldwide results of the RELIEF study. Reflux assEssment and quaLity of lIfe improvEment with micronized Flavonoids.
    Jantet G
    Angiology; 2002; 53(3):245-56. PubMed ID: 12025911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of micronized purified flavonoid fraction (Daflon®) on improving individual symptoms, signs and quality of life in patients with chronic venous disease: a systematic review and meta-analysis of randomized double-blind placebo-controlled trials.
    Kakkos SK; Nicolaides AN
    Int Angiol; 2018 Apr; 37(2):143-154. PubMed ID: 29385792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RELIEF study: first consolidated European data. Reflux assEssment and quaLity of lIfe improvement with micronized Flavonoids.
    Jantet G
    Angiology; 2000 Jan; 51(1):31-7. PubMed ID: 10667641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Micronised purified flavonoid fraction: a review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids.
    Lyseng-Williamson KA; Perry CM
    Drugs; 2003; 63(1):71-100. PubMed ID: 12487623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daflon 500 mg: symptoms and edema clinical update.
    Ramelet AA
    Angiology; 2005; 56 Suppl 1():S25-32. PubMed ID: 16193223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of orally administered extract of red vine leaf AS 195 (folia vitis viniferae) in chronic venous insufficiency (stages I-II). A randomized, double-blind, placebo-controlled trial.
    Kiesewetter H; Koscielny J; Kalus U; Vix JM; Peil H; Petrini O; van Toor BS; de Mey C
    Arzneimittelforschung; 2000 Feb; 50(2):109-17. PubMed ID: 10719612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical benefits of Daflon 500 mg in the most severe stages of chronic venous insufficiency.
    Ramelet AA
    Angiology; 2001 Aug; 52 Suppl 1():S49-56. PubMed ID: 11510597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical efficacy of micronized purified flavonoid fraction: an overview.
    Struckmann JR
    J Vasc Res; 1999; 36 Suppl 1():37-41. PubMed ID: 10474049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical acceptability study of once-daily versus twice-daily micronized purified flavonoid fraction in patients with symptomatic chronic venous disease: a randomized controlled trial.
    Kirienko A; Radak D
    Int Angiol; 2016 Aug; 35(4):399-405. PubMed ID: 26576663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of lower-limb edema in patients with chronic venous disease by micronized purified flavonoid fraction: a systematic literature review and meta-analysis.
    Rabe E; Blanc-Guillemaud V; Onselaer MB; Blangero Y; Yaltirik HP; Nicolaides A
    Int Angiol; 2023 Dec; 42(6):488-502. PubMed ID: 38131655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From symptoms to leg edema: efficacy of Daflon 500 mg.
    Nicolaides AN
    Angiology; 2003; 54 Suppl 1():S33-44. PubMed ID: 12934755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recommendations for the medical management of chronic venous disease: The role of Micronized Purified Flavanoid Fraction (MPFF).
    Bush R; Comerota A; Meissner M; Raffetto JD; Hahn SR; Freeman K
    Phlebology; 2017 Apr; 32(1_suppl):3-19. PubMed ID: 28211296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy of once-daily micronized purified flavonoid fraction 1000 mg tablet in patients with symptomatic chronic venous disease.
    Kirienko A; Radak D; Maggioli A
    Curr Med Res Opin; 2019 Mar; 35(3):553-557. PubMed ID: 29992831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of the effects of micronized purified flavonoid fraction versus placebo on symptoms and quality of life in patients suffering from chronic venous disease: from a prospective randomized trial.
    Rabe E; Agus GB; Roztocil K
    Int Angiol; 2015 Oct; 34(5):428-36. PubMed ID: 25972136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparative efficacy of various methods of treatment of chronic venous oedema in real clinical practice].
    Bogachev VI; Boldin BV; Turkin PI; Samenkov AI;
    Angiol Sosud Khir; 2021; 27(3):77-83. PubMed ID: 34528591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomised controlled trial of micronised purified flavonoid fraction vs placebo in patients with chronic venous disease.
    Danielsson G; Jungbeck C; Peterson K; Norgren L
    Eur J Vasc Endovasc Surg; 2002 Jan; 23(1):73-6. PubMed ID: 11748952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Micronized purified flavonoid fraction for the treatment of chronic venous insufficiency, with a focus on postthrombotic syndrome: A narrative review.
    Li KX; Diendéré G; Galanaud JP; Mahjoub N; Kahn SR
    Res Pract Thromb Haemost; 2021 May; 5(4):e12527. PubMed ID: 34027293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Daflon 500 mg in the treatment of lymphedema (secondary to conventional therapy of breast cancer).
    Pecking AP; Février B; Wargon C; Pillion G
    Angiology; 1997 Jan; 48(1):93-8. PubMed ID: 8995350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.